NASDAQ:LXEO
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. reported net income of −$100.0M in fiscal 2025. Free cash flow was −$99.0M, and the diluted share count rose 68.8%.Summary generated from Lexeo Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−55.0%
Debt / equityn/a
Free cash flow−$99.0M
FCF marginn/a
Share count change+68.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 1 | n/a | n/a | n/a |
| Operating income | −61 | −69 | −106 | −109 |
| Net income | −59 | −66 | −98 | −100 |
| Free cash flow | −55 | −60 | −82 | −99 |
Recent filings
- 8-KCompletion of an acquisition or disposition
Sep 29, 2026 - 4Insider transaction report
Sep 28, 2026 - 4Insider transaction report
Sep 28, 2026 - 8-KEntry into a material agreement
Sep 22, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KResults of a shareholder vote
Jun 29, 2026 - 8-KRegulation FD disclosure
Jun 15, 2026